审核意见 证券代码：301033 证券简称：迈普医学 公告编号：2024-061 本次归属的 46 名激励对象具备《公司法》《证券法》等法律、 法规和规范性文件以及《公司章程》规定的任职资格，符合《管理办 法》《上市规则》等有关法律、行政法规及规范性文件规定的激励对 象条件，符合本次激励计划规定的激励对象范围，其作为公司本次激 励计划激励对象的主体资格合法、有效，激励对象获授的限制性股票 第一个归属期归属条件已成就。监事会同意公司为本次符合条件的 46 审核意见 名激励对象办理归属事宜，对应限制性股票的归属数量为 504,480 股。 上述事项符合相关法律、行政法规及规范性文件所规定的条件，不存 在损害公司及股东利益的情形。 特此公告。 广州迈普再生医学科技股份有限公司 监事会 广州迈普再生医学科技股份有限公司 监事会关于 2023 年限制性股票激励计划 首次授予部分第一个归属期归属名单的核查意见 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 广州迈普再生医学科技股份有限公司（以下简称"公司"）监事 会根据《上市公司股权激励管理办法》（以下简称"《管理办法》 ...

Group 1: Company Overview - Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. is focused on neurosurgery, providing comprehensive solutions for neurosurgical repairs [2][3]. - The company is the only domestic enterprise with a range of implantable medical devices, including artificial dura mater patches and absorbable regenerated cellulose [3][4]. Group 2: Future Strategies - The company aims to enhance its marketing system and expand its market share in the neurosurgery field, targeting a broader product portfolio [3][4]. - Plans include extending technology applications to other surgical fields, such as hemostatic products and dental restoration [3][4]. Group 3: Market Presence - The dura mater medical glue has been sold in over 20 countries and regions, including Europe and Asia, with corresponding registrations obtained [4]. - The company is committed to maintaining its competitive advantage in the neurosurgery sector while exploring new product lines to meet clinical needs [3][4]. Group 4: Investor Engagement - The company held an investor relations activity on September 12, 2024, to address investor inquiries regarding future sales strategies and market share [2][3]. - Investors were encouraged to reach out for further inquiries or suggestions through the investor hotline [4].

Group 1: Event Details - The company will participate in the "2024 Guangdong Listed Companies Investor Online Reception Day" organized by the China Securities Regulatory Commission Guangdong Supervision Bureau and Guangdong Listed Companies Association [2] - The event will be held online on September 12, 2024, from 15:30 to 16:30 [2] - Investors can join the event via the "Panorama Roadshow" website (https://rs.p5w.net) [2] Group 2: Company Representatives - The event will feature company representatives including Chairman Yuan Yuyu, General Manager Wang Jianhua, and Financial Director Luo Yahui [2] - The presence of the Board Secretary Long Xiaoyan is also confirmed for the event [2] Group 3: Commitment to Transparency - The company and its board members guarantee the authenticity, accuracy, and completeness of the information disclosed, with no false records or misleading statements [2]

Investment Rating - The report maintains a "Recommended" investment rating for the company with a target price of 51 CNY, based on a current price of 40.48 CNY [1]. Core Views - The company reported a significant revenue growth of 42.39% year-on-year, reaching 1.22 billion CNY in the first half of 2024, with a net profit increase of 172.38% to 320 million CNY [1]. - New products are rapidly gaining market traction, with the absorbable regenerated oxidized cellulose and dura mater medical adhesive generating 140 million CNY in revenue, a 145% increase [1]. - The international business is expanding, with overseas revenue growing by 25.71% to 250 million CNY, covering nearly 90 countries and regions [1]. - The overall gross margin slightly decreased to 78.85%, primarily due to the impact of centralized procurement, while the net profit margin improved to 26.54% due to optimized expenses [1]. Financial Summary - Total revenue for 2023 is projected at 231 million CNY, with expected growth rates of 25.4% in 2024, 33.7% in 2025, and 35.4% in 2026 [2]. - The net profit for 2023 is estimated at 41 million CNY, with a forecasted increase to 61 million CNY in 2024, 84 million CNY in 2025, and 122 million CNY in 2026, reflecting growth rates of 49.1%, 38.1%, and 45.5% respectively [2]. - Earnings per share (EPS) are projected to rise from 0.62 CNY in 2023 to 0.92 CNY in 2024, 1.27 CNY in 2025, and 1.85 CNY in 2026 [2]. Business Performance - The dura mater segment achieved a revenue of 690 million CNY in the first half of 2024, marking a 36.68% year-on-year increase [1]. - The craniofacial repair and fixation systems generated 350 million CNY in revenue, up 32.79% year-on-year [1]. - The company has implemented a stock incentive plan for 2024, aiming for revenue growth targets of no less than 23%, 61%, and 103% for the years 2024 to 2026, respectively [1].

关于公司实际控制人、控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份解除质押基本情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）近日 接到公司实际控制人、控股股东袁玉宇先生的函告，获悉其所持有的 公司部分股份办理了解除质押手续，具体情况如下： （二）股东股份累计质押情况 截至本公告披露日，上述股东及其一致行动人所持质押股份情况 股份解除质押的公告 证券代码：301033 证券简称：迈普医学 公告编号：2024-055 广州迈普再生医学科技股份有限公司 二、其他情况说明 截至公告披露日，公司实际控制人、控股股东所持股份不存在被 冻结或拍卖等情况，其所质押的股份不存在平仓风险。上述股份解除 股份解除质押的公告 质押行为不会导致公司实际控制权变更，对公司生产经营、公司治理 不会产生重大影响。实际控制人及其一致行动人将积极防范风险。 （一）股东股份解除质押基本情况 股东名称 是否为控股 股东或第一 大股东及其 一致行为人 本次解除 质押数量 （股） 占其所 持股份 比例（%） 占公司 总股本 比例（%） 质押起 始 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage of the stock [1][3]. Core Insights - The company achieved a revenue of 122.05 million yuan, representing a year-on-year growth of 42.39%, and a net profit attributable to shareholders of 32.39 million yuan, which is a 172.38% increase compared to the previous year [1]. - The report highlights the increasing market penetration of the company's products due to successful bidding in various regional procurement initiatives, leading to a significant sales revenue growth of 36.68% for its meninges products in the first half of 2024 [1]. - The potential for PEEK materials to replace titanium alloys in craniofacial repair and fixation systems is noted, with the company reporting a 32.79% increase in sales revenue for these products [1]. - The company has developed absorbable regenerated hemostatic gauze, breaking the long-standing import monopoly in the domestic market, with over 80,000 pieces used in clinical settings in the first half of 2024 [1]. - The international sales revenue reached 25.41 million yuan in the first half of 2024, a 25.71% increase year-on-year, accounting for 20.82% of total revenue, providing a buffer against domestic market price fluctuations [2]. Summary by Sections Financial Performance - The company reported a significant increase in revenue and net profit, with projections for 2024-2026 indicating revenues of 304 million, 382 million, and 461 million yuan respectively, and net profits of 62 million, 92 million, and 124 million yuan [3][5]. - The earnings per share (EPS) are forecasted to be 0.93, 1.39, and 1.87 yuan for the years 2024, 2025, and 2026, respectively, with corresponding price-to-earnings (PE) ratios of 43.5, 29.3, and 21.7 [3][5]. Market Position and Strategy - The company has established a strong international presence, having obtained CE certification for its absorbable dura (spinal) membrane patches in March 2011, and has been actively expanding into overseas markets [1]. - The report emphasizes the company's robust digital design and precision processing capabilities, which are expected to support its growth in the PEEK materials market [1].

也受益集财快速发展 新产品潜力空间巨大我们也是结合这两点向推荐未来公司有望持续多年业绩较快增长然后当前这个位置也是建议几个投资者积极的买入我们首先请董美伦和艾亚总给我们就上半年的经营情况做个介绍后续我们会采访券商和投资者问答环节先请沈阳总 好的 谢谢郑老师首先感谢华春莹先生以及各位先生老师共同组织的本次的交流我是脉搏医学的龙小燕我下面简单介绍一下公司半年度的情况脉搏医学目前的话我们是整个外科领域唯一拥有人工智能脉搏以及颅和面修补和固定系统以及可吸收止血杀以及脑膜胶的产品的企业 目前我们已经能够为行政外科的手术提供整体的关国解决方案2024年的上半年公司的整体营收是1.2亿人民币然后比上一年同期增长了42.39%然后归属于上市公司股东的经济利润3200万比上一年同期增长了172%归属于上市公司扣非的经济利润为2700多万 然后比上一年同期增长了193而且的话我们公司2023年因为实施第二期股权激励然后本报告期的话会有股份支付的这个影响那么把相应的这个股份支付数提出之后的话公司归属于上市公司股东的这个经历润为3800万同比增长了4%是222那么实现归属于上市公司扣费经历润是3300多万然后同比增长是257 那么其 ...

华福证券 产品研发失败的风险、产品销量不及预期的风险、市场竞争加剧 司 研 迈普医学（301033.SZ） 集采执行带动放量加速，业绩表现亮眼 投资要点： 事件：公司发布 2024 年半年报，2024H1 实现收入 1.2 亿（同比+42.4%）， 归母净利润 3239 万（同比+172.4%），扣非归母净利润 2768 万（同比 +193.9%）；2024Q2：实现收入 6484 万（同比+57.3%），归母净利润 1745 万（同比+328.1%），扣非归母净利润 1560 万（同比+426.6%）。 Q2 脑膜集采执行放量+去年同期低基数，新老产品增速均亮眼：分产 品来看：1）人工硬脑（脊）膜补片 2024H1 实现收入 6911 万（同比+36.7%）。 2023 年公司产品陆续在安徽、江苏、辽宁省联盟、山西联盟集采中标/续约， 伴随着 24 年集采执行，公司产品渗透率提升，放量加速趋势明显，叠加同 期集采渠道库存出清较低基数，上半年实现高速增长；2）PEEK 颅颌面修 补 2024H1 实现收入 3549 万（同比+32.8%)。国内 PEEK 材料渗透率低， 市场空间广阔。2023 年 11 月河 ...

Financial Performance - The company reported a revenue of RMB 150 million for the first half of 2024, representing a 25% increase compared to RMB 120 million in the same period of 2023[7]. - The company's operating revenue for the reporting period was ¥122,046,806.09, representing a 42.39% increase compared to ¥85,715,500.25 in the same period last year[13]. - The net profit attributable to shareholders was ¥32,390,679.79, a significant increase of 172.38% from ¥11,891,627.77 year-on-year[13]. - The basic earnings per share rose to ¥0.49, up 172.22% from ¥0.18 in the previous year[13]. - The company achieved operating revenue of 122.05 million yuan, a year-on-year increase of 42.39%[24]. - Net profit attributable to shareholders reached 32.39 million yuan, up 172.38% year-on-year[24]. - The company reported a net profit for the first half of 2024 was ¥42,710,975.27, compared to ¥7,446,316.22 in the first half of 2023, reflecting a substantial growth of 473.5%[106]. - The total operating profit for the first half of 2024 was ¥46,932,698.77, up from ¥8,031,738.33 in the previous year, indicating a growth of 484.5%[106]. Market Expansion and Strategy - The company plans to invest RMB 30 million in R&D for new product development in the next fiscal year, focusing on advanced medical devices and bioprinting technologies[7]. - User data indicates a 40% increase in the adoption of the company's medical devices in hospitals across China, with over 500 new hospital partnerships established in the first half of 2024[7]. - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of 2024[7]. - The company has successfully completed the acquisition of a local medical technology firm, enhancing its product portfolio and market reach[7]. - The company plans to expand the market penetration of its hemostatic materials, aiming to compete with imported brands[28]. - The company is actively exploring market expansion strategies and new product development initiatives[89]. - The company is considering potential mergers and acquisitions to enhance its market position[89]. Research and Development - The company is focusing on the development of biodegradable medical materials, aiming to launch a new product line by Q4 2024[7]. - The company’s R&D capabilities are recognized nationally, with multiple awards and certifications, including being a national-level "little giant" enterprise[30]. - Research and development investment decreased by 45.78% to CNY 12.13 million, influenced by the progress of R&D project cycles[35]. - The company plans to strengthen its R&D capabilities and improve innovation to mitigate risks associated with new technology iterations[48]. - The company is developing a second-generation dural membrane product, which is expected to differ significantly from the first generation, and is focusing on the rapid growth and market share of PEEK materials[55]. Financial Management - The company has not declared any cash dividends for the current fiscal year, opting to reinvest profits into growth initiatives[2]. - The company reported non-recurring gains of ¥4,714,531.64, primarily from government subsidies and other income[16][17]. - The company has a stable operating model and has not experienced significant changes in its main business during the reporting period[19]. - The company reported a total of ¥24,579.9 million in entrusted financial management, with an outstanding balance of ¥16,198 million[44]. - The company has maintained a stable and positive profit distribution policy to share development results with investors[65]. - The company reported a total cash outflow from financing activities of ¥89,086,951.94, which is more than double the outflow of ¥40,290,357.05 in the same period last year[111]. Risk Management - The company emphasizes the importance of risk management in its operations, particularly in the context of regulatory compliance and market fluctuations[2]. - The company faces risks from policy changes in the high-value medical device industry, which could adversely affect its operations[49]. - The company is facing intensified market competition in the neurosurgery high-value medical consumables sector due to increasing incidence rates of neurological diseases and the entry of numerous domestic and international competitors[51]. Corporate Governance and Compliance - The company has not reported any non-compliance with external guarantees during the reporting period[71]. - The company has not engaged in any significant related party transactions during the reporting period[71]. - The company reported no significant litigation or arbitration matters during the reporting period[69]. - The financial report for the first half of 2024 has not been audited[95]. - The company adheres to the accounting standards and principles set forth by the relevant authorities, ensuring accurate financial reporting[131]. Shareholder Information - The largest shareholder, Yuan Yuyu, holds 16.63% of the shares, totaling 10,987,847, with a pledge of 4,910,000 shares[87]. - The second-largest shareholder, Xu Tao, holds 16.53% of the shares, totaling 10,922,547[87]. - The company has 5,255 common shareholders at the end of the reporting period[87]. - The company has completed its share repurchase plan, with the total repurchase funds exceeding the lower limit of the plan[86]. Social Responsibility - The company has awarded 2,348 students and 748 teachers through its scholarship fund from 2021 to 2023, supporting education in rural areas[68]. - The company has actively participated in social welfare activities, including providing free surgical materials for a child in need[68].

华泰联合证券有限责任公司关于 广州迈普再生医学科技股份有限公司 2024 年半年度持续督导跟踪报告 | 保荐人名称：华泰联合证券有限责任公司 | 被保荐公司简称：迈普医学 | | --- | --- | | 保荐代表人姓名：刘恺 | 联系电话：0755-82492010 | | 保荐代表人姓名：张冠峰 | 联系电话：0755-82492010 | 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 次 0 | | 2、督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限 于防止关联方占用公司资源的制度、募集资金管理 | 是 | | 制度、内控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 不适用，募集资金专户已于 2021 年注销 | | （2）公司募集资金项目进展是否与信息披露文件 ...